Akademiska Hospital
Uppsala, Uppland, SE75185, Sweden
NCT Number: NCT01216033
The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.
Looking for future studies?
Notify Me20 year and older
Female
Interventional
Phase 1 / Phase 2
Uppsala, Uppland, SE75185, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous injection of the agent
Time frame: One year
Imaging of breast cancer metastases using 111-In-ABY015 for SPECT
Time frame: October 2010 - June 2011
Biomedical Radiation Sciences
Other
An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer
Acronym: ABY0125
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00317720
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsNCT06253195
Advanced Solid Tumor, Breast Cancer
Beijing, Beijing Municipality, China
View Trial DetailsNCT01560416
Breast Cancer, Breast Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04991480
Advanced Cancer, Breast Cancer
New Haven, Connecticut, United States
View Trial Details